Component

Erythrocyte pyridoxamine/pyridoxine phosphate oxidase activity

Measured process or biological entity; consult each linked claim for the experimental scope.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Low FMN-dependent PNP oxidase activity in many G6PD-deficient participants responded to oral riboflavin despite the contrasting FAD-saturated GSR pattern.

    Riboflavin (vitamin B2) → Erythrocyte pyridoxamine/pyridoxine phosphate oxidase activity source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    cross_nutrient
    B2 cofactor supply affects a B6-activation assay.
    experimental_model
    Human erythrocytes from G6PD deficiency, heterozygous beta-thalassemia and controls.
    exposure
    In-vitro FAD stimulation of glutathione reductase and PNP oxidase activity, with oral-riboflavin response observations.
    limitations
    No isolated whole-body B6 flux or clinical seizure/neuropathy outcome was established.
    nutrient_topic
    Riboflavin research collection; topical membership is not evidence of a direct dietary effect. · Riboflavin (vitamin B2)
    organism
    Homo sapiens
    plain_language
    FMN and FAD should not be treated as one interchangeable vitamin pool.
    primary_references
    [b2-anderson1987] Glutathione reductase activity and its relationship to pyridoxine phosphate activity in G6PD deficiency (1987). https://pubmed.ncbi.nlm.nih.gov/3582603/ DOI: 10.1111/j.1600-0609.1987.tb01417.x
    tissue_or_cell_type
    Human clinical setting
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    Riboflavin: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1679–1690

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human erythrocytes from G6PD deficiency, heterozygous beta-thalassemia and controls. · source_derived_draft · unverified_draft

    ### b2-g6pd-fmn-oxidase-response Low FMN-dependent PNP oxidase activity in many G6PD-deficient participants responded to oral riboflavin despite the contrasting FAD-saturated GSR pattern. Condition category: biomarker_context nutrient_topic: Riboflavin research collection; topical membership is not evidence of a direct dietary effect. plain_language: FMN and FAD should not be treated as one interchangeable vitamin pool. organism: Homo sapiens tissue_or_cell_type: Human clinical setting experimental_model: Human erythrocytes from G6PD deficiency, heterozygous beta-thalassemia and controls. limitations: No isolated whole-body B6 flux or clinical seizure/neuropathy outcome was established. exposure: In-vitro FAD stimulation of glutathione reductase and PNP oxidase activity, with oral-riboflavin response observations. cross_nutrient: B2 cofactor supply affects a B6-activation assay. [b2-anderson1987] Glutathione reductase activity and its relationship to pyridoxine phosphate activity in G6PD deficiency (1987). https://pubmed.ncbi.nlm.nih.gov/3582603/ DOI: 10.1111/j.1600-0609.1987.tb01417.x
    Complete structured claim and evidence

  2. Erythrocyte PPO activity and its activation coefficient responded to B2 supplementation and correlated with EGRAC; enzyme activity showed a dose response.

    Riboflavin (vitamin B2) → Erythrocyte pyridoxamine/pyridoxine phosphate oxidase activity source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    cross_nutrient
    A B6-activation enzyme provides a B2-sensitive functional assay.
    experimental_model
    Assay-development study using hemolysates from the RIBOFEM riboflavin intervention; same trial registration ISRCTN35811298.
    exposure
    Erythrocyte PPO activity with/without flavin activation; 2 and 4 mg/day supplementation arms. Not independent replication of RIBOFEM.
    limitations
    Assay-development analysis shares samples with RIBOFEM; not independent replication. Proposed utility in G6PD deficiency requires population-specific validation.
    nutrient_topic
    Riboflavin research collection; topical membership is not evidence of a direct dietary effect. · Riboflavin (vitamin B2)
    organism
    Homo sapiens
    plain_language
    An enzyme used to activate B6 can also reveal aspects of B2 status because it needs an FMN cofactor.
    primary_references
    [b2-mushtaq2009] Erythrocyte pyridoxamine phosphate oxidase activity: a potential biomarker of riboflavin status? (2009). https://pubmed.ncbi.nlm.nih.gov/19740970/ DOI: 10.3945/ajcn.2009.28338
    tissue_or_cell_type
    Human clinical setting
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    Riboflavin: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1653–1664

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Assay-development study using hemolysates from the RIBOFEM riboflavin intervention; same trial registration ISRCTN35811298. · source_derived_draft · unverified_draft

    ### b2-ppo-biomarker-response Erythrocyte PPO activity and its activation coefficient responded to B2 supplementation and correlated with EGRAC; enzyme activity showed a dose response. Condition category: biomarker_context nutrient_topic: Riboflavin research collection; topical membership is not evidence of a direct dietary effect. plain_language: An enzyme used to activate B6 can also reveal aspects of B2 status because it needs an FMN cofactor. organism: Homo sapiens tissue_or_cell_type: Human clinical setting experimental_model: Assay-development study using hemolysates from the RIBOFEM riboflavin intervention; same trial registration ISRCTN35811298. limitations: Assay-development analysis shares samples with RIBOFEM; not independent replication. Proposed utility in G6PD deficiency requires population-specific validation. exposure: Erythrocyte PPO activity with/without flavin activation; 2 and 4 mg/day supplementation arms. Not independent replication of RIBOFEM. cross_nutrient: A B6-activation enzyme provides a B2-sensitive functional assay. [b2-mushtaq2009] Erythrocyte pyridoxamine phosphate oxidase activity: a potential biomarker of riboflavin status? (2009). https://pubmed.ncbi.nlm.nih.gov/19740970/ DOI: 10.3945/ajcn.2009.28338
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards